Evidence map›Paper›PMID 41538474›Full record

ArticleEinstein (Sao Paulo, Brazil)2026

Characterization of a novel MSH2 variant in Lynch syndrome: clinical data and complementary bioinformatics assessment.

Anisse Marques Chami, Thalia Rodrigues de Souza Zózimo, Carolina Guimarães Ramos Matosinho, Agnaldo Lopes da Silva-Filho, Maria Raquel Santos Carvalho, Letícia da Conceição Braga

Abstract readCase Reports
In one paragraph

Article in Einstein (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anisse Marques ChamiPostgraduate Program in Obstetrics and Gynecology, Faculdade de Medicina, Universidade Estadual Paulista "Júlio de Mesquita Filho", Botucatu, SP, Brazil.ORCID http://orcid.org/0000-0002-2651-0995
Thalia Rodrigues de Souza ZózimoDepartment of Genetics, Ecology and Evolution, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0001-8473-2548
Carolina Guimarães Ramos MatosinhoDepartment of Genetics, Ecology and Evolution, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0001-8070-1031
Agnaldo Lopes da Silva-FilhoDepartment of Gynecology and Obstetrics, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0002-8486-7861
Maria Raquel Santos CarvalhoDepartment of Genetics, Ecology and Evolution, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0002-1744-448X
Letícia da Conceição BragaPostgraduate Programa in Genetics, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.ORCID http://orcid.org/0000-0002-6181-9410

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the clinical characteristics and perform a multi-step bioinformatics evaluation of the pathogenicity of NM_000251.3(MSH2):c.1894_1898del (p.Ile633Lysfs*9), an MSH2 germline variant detected in a family with Lynch syndrome.

methodsClinical evaluation included description of phenotype, family history, and immunohistochemical characterization of the proband's tumors. For pathogenicity classification according to the American College of Genetics and Genomics/Association for Molecular Pathology (ACMG/APA) criteria, bioinformatics analyses included: (i) literature and database screening, searching for the variant allele frequency, case reports, or functional studies, including ClinVar, VarSome, Ensembl, PubMed, EVA, and ABraOM; (ii) prediction of variant impacts using ExPASy Translate, Pfam, and Modeller 9.24; and, (iii) mechanisms that could mitigate the effects of the variant included alternative splicing and exon skipping (UniProt and GTex) and nonsense-mediated decay (NMD; MutationTaster2021).

resultsThe proband, a 55-year-old female, was diagnosed with two metachronous colorectal cancers. Immunohistochemical analysis showed loss of expression ( MSH2 in one tumor, and MSH2 and MSH6 in the other). Seven deceased family members were diagnosed with cancer (four colorectal, one uterine, and two unspecified). This variant caused a stop codon in MSH2 exon 12 of 16. When translated, the protein loses 294 C-terminal residues, which may prompt protein degradation. If the mutated protein escapes degradation, dimerization and DNA-binding domains will be present. Therefore, negative dominance effects were possible. No isoforms ending in exon 12 have been identified in the literature or in RNA splicing databases. A stop codon before the last exon-exon boundary indicated the occurrence of NMD.

conclusionNo evidence of protein-rescuing mechanisms was found, supporting the classification of this variant as likely pathogenic/pathogenic.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisMutS Homolog 2 ProteinComputational BiologyFemaleGerm-Line MutationHumansImmunohistochemistryMaleMiddle AgedPedigreePhenotypeMSH2 protein, humanMutS Homolog 2 Protein

Identifiers

PMID41538474
PMCPMC12713438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.